Search Results 141-150 of 15070 for infliximab
This study will evaluate the efficacy and safety of two adalimumab induction regimens in subjects with moderately to severely active Crohn's disease and ...
Learn about symptoms and treatment for this debilitating, but treatable, digestive condition.
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the ...
... infliximab, adalimumab, certolizumab, or vedolizumab). Exclusion Criteria: • The presence of any of the following will exclude a subject from enrollment ...
8 week washout for infliximab or adalimumab; 2 week washout for etanercept; 1 week washout for anakinra. If an IS agent is continued, the dose must remain ...
Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
At least one 6-week induction regimen of infliximab (≥ 5 mg/kg intravenous [IV] ... approved biologic agent (e.g., infliximab, adalimumab, golimumab ...
infliximab), chemotherapy) or imunosuppressive condition (ex. transplant, immunodeficiency syndromes, HIV/AIDS); Auto-immune disease (ex. lupus, rheumatoid ...
... . VID-20381052. Home; Pharmacogenomics. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in impact thanks to a ...
Radiologists at Mayo Clinic were instrumental in developing novel bowel imaging techniques, including magnetic resonance (MR) and CT enterography. Current ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.